Marker Therapeutics, Inc.

Monthly Archives: March 2018

TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast

Please join us for our fourth quarterly call and year end update of 2017 on April 5, 2018 at 4:30pm.
Read More

TapImmune to Present at The MicroCap Conference

TapImmune President and CEO, Peter Hoang, to present at 2018 The Microcap Conference.
Read More

TapImmune’s Cancer Vaccine Significantly Extends Progression Free Survival In Ovarian Cancer

TapImmune’s cancer vaccine significantly extended progression free survival of ovarian cancer patients, as compared to the current standard of care.
Read More

Phase 1 Trial Finds TPIV200 Is Safe, Delays Recurrence in Ovarian, Breast Cancer

An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete responses in a Phase 1 trial.
Read More

Is TapImmune’s Cancer Vaccine the Real Deal?

TapImmune released some interesting results this week from a Phase I trial conducted at the Mayo Clinic that will add some spice to that discussion.
Read More

Ovarian and Breast Cancer Vaccine Candidate Posts Positive Clinical Trial Results

TPIV200 vaccine candidate showed 90% of patients developed robust and durable antigen-specific immune responses against FRa.
Read More

TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research

The publication of clinical data from a Phase 1 trial of TPIV200, the company’s multi-epitope T-cell vaccine targeting Folate Receptor Alpha in patients with ovarian and breast cancer will be available online today.
Read More

TapImmune to Present at Two Upcoming Investor Conferences

TapImmune President & CEO, Peter Hoang, will be participating in two conferences next week.
Read More